FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice

Jing Li, Jun Song, Xian Li, Stephanie B. Rock, Heather F. Sinner, Heidi L. Weiss, Todd Weiss, Courtney Townsend, Tianyan Gao, B. Mark Evers

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neurotensin (NT), a 13 amino-acid peptide, is predominantly released from enteroendocrine cells of the small bowel in response to fat ingestion. Free fatty acid receptors (FFARs) FFAR1 and FFAR4 regulate secretion of gut hormones and insulin. Here, we show that docosahexaenoic acid, a longchain fatty acid, has the most dramatic effect on NT release. FFAR1 agonists slightly stimulate and FFAR4 agonists dramatically stimulate and amplify NT secretion. Double knockdown of FFAR1 and FFAR4 decreases NT release, whereas overexpression of FFAR4, but not FFAR1, increases NT release. Administration of cpdA, an FFAR4 agonist, but not TAK-875, a selective FFAR1 agonist, increases plasma NT levels and further increases olive oil-stimulated plasma NT levels. Inhibition of MAPK kinase (MEK)/ERK1/2 decreased fatty acid-stimulated NT release but increased AMP-activated protein kinase (AMPK) phosphorylation. In contrast, inhibition of AMPK further increased NT secretion and ERK1/2 phosphorylation mediated by FFAR1 or FFAR4. Our results indicate that FFAR4 plays a more critical role than FFAR1 in mediation of fat-regulated NT release and in inhibitory crosstalk between MEK/ERK1/2 and AMPK in the control of NT release downstream of FFAR1 and FFAR4.

Original languageEnglish (US)
Pages (from-to)2939-2952
Number of pages14
JournalEndocrinology
Volume159
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Neuroendocrine Cells
Neurotensin
Inbred C57BL Mouse
AMP-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Fatty Acids
Fats
Phosphorylation
Enteroendocrine Cells
Docosahexaenoic Acids
Nonesterified Fatty Acids
Eating
Hormones
Insulin

ASJC Scopus subject areas

  • Endocrinology

Cite this

Li, J., Song, J., Li, X., Rock, S. B., Sinner, H. F., Weiss, H. L., ... Evers, B. M. (2018). FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice. Endocrinology, 159(8), 2939-2952. https://doi.org/10.1210/en.2018-00284

FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice. / Li, Jing; Song, Jun; Li, Xian; Rock, Stephanie B.; Sinner, Heather F.; Weiss, Heidi L.; Weiss, Todd; Townsend, Courtney; Gao, Tianyan; Evers, B. Mark.

In: Endocrinology, Vol. 159, No. 8, 01.08.2018, p. 2939-2952.

Research output: Contribution to journalArticle

Li, J, Song, J, Li, X, Rock, SB, Sinner, HF, Weiss, HL, Weiss, T, Townsend, C, Gao, T & Evers, BM 2018, 'FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice', Endocrinology, vol. 159, no. 8, pp. 2939-2952. https://doi.org/10.1210/en.2018-00284
Li, Jing ; Song, Jun ; Li, Xian ; Rock, Stephanie B. ; Sinner, Heather F. ; Weiss, Heidi L. ; Weiss, Todd ; Townsend, Courtney ; Gao, Tianyan ; Evers, B. Mark. / FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice. In: Endocrinology. 2018 ; Vol. 159, No. 8. pp. 2939-2952.
@article{8d18af4719b640eea22e007542a2557e,
title = "FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice",
abstract = "Neurotensin (NT), a 13 amino-acid peptide, is predominantly released from enteroendocrine cells of the small bowel in response to fat ingestion. Free fatty acid receptors (FFARs) FFAR1 and FFAR4 regulate secretion of gut hormones and insulin. Here, we show that docosahexaenoic acid, a longchain fatty acid, has the most dramatic effect on NT release. FFAR1 agonists slightly stimulate and FFAR4 agonists dramatically stimulate and amplify NT secretion. Double knockdown of FFAR1 and FFAR4 decreases NT release, whereas overexpression of FFAR4, but not FFAR1, increases NT release. Administration of cpdA, an FFAR4 agonist, but not TAK-875, a selective FFAR1 agonist, increases plasma NT levels and further increases olive oil-stimulated plasma NT levels. Inhibition of MAPK kinase (MEK)/ERK1/2 decreased fatty acid-stimulated NT release but increased AMP-activated protein kinase (AMPK) phosphorylation. In contrast, inhibition of AMPK further increased NT secretion and ERK1/2 phosphorylation mediated by FFAR1 or FFAR4. Our results indicate that FFAR4 plays a more critical role than FFAR1 in mediation of fat-regulated NT release and in inhibitory crosstalk between MEK/ERK1/2 and AMPK in the control of NT release downstream of FFAR1 and FFAR4.",
author = "Jing Li and Jun Song and Xian Li and Rock, {Stephanie B.} and Sinner, {Heather F.} and Weiss, {Heidi L.} and Todd Weiss and Courtney Townsend and Tianyan Gao and Evers, {B. Mark}",
year = "2018",
month = "8",
day = "1",
doi = "10.1210/en.2018-00284",
language = "English (US)",
volume = "159",
pages = "2939--2952",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice

AU - Li, Jing

AU - Song, Jun

AU - Li, Xian

AU - Rock, Stephanie B.

AU - Sinner, Heather F.

AU - Weiss, Heidi L.

AU - Weiss, Todd

AU - Townsend, Courtney

AU - Gao, Tianyan

AU - Evers, B. Mark

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Neurotensin (NT), a 13 amino-acid peptide, is predominantly released from enteroendocrine cells of the small bowel in response to fat ingestion. Free fatty acid receptors (FFARs) FFAR1 and FFAR4 regulate secretion of gut hormones and insulin. Here, we show that docosahexaenoic acid, a longchain fatty acid, has the most dramatic effect on NT release. FFAR1 agonists slightly stimulate and FFAR4 agonists dramatically stimulate and amplify NT secretion. Double knockdown of FFAR1 and FFAR4 decreases NT release, whereas overexpression of FFAR4, but not FFAR1, increases NT release. Administration of cpdA, an FFAR4 agonist, but not TAK-875, a selective FFAR1 agonist, increases plasma NT levels and further increases olive oil-stimulated plasma NT levels. Inhibition of MAPK kinase (MEK)/ERK1/2 decreased fatty acid-stimulated NT release but increased AMP-activated protein kinase (AMPK) phosphorylation. In contrast, inhibition of AMPK further increased NT secretion and ERK1/2 phosphorylation mediated by FFAR1 or FFAR4. Our results indicate that FFAR4 plays a more critical role than FFAR1 in mediation of fat-regulated NT release and in inhibitory crosstalk between MEK/ERK1/2 and AMPK in the control of NT release downstream of FFAR1 and FFAR4.

AB - Neurotensin (NT), a 13 amino-acid peptide, is predominantly released from enteroendocrine cells of the small bowel in response to fat ingestion. Free fatty acid receptors (FFARs) FFAR1 and FFAR4 regulate secretion of gut hormones and insulin. Here, we show that docosahexaenoic acid, a longchain fatty acid, has the most dramatic effect on NT release. FFAR1 agonists slightly stimulate and FFAR4 agonists dramatically stimulate and amplify NT secretion. Double knockdown of FFAR1 and FFAR4 decreases NT release, whereas overexpression of FFAR4, but not FFAR1, increases NT release. Administration of cpdA, an FFAR4 agonist, but not TAK-875, a selective FFAR1 agonist, increases plasma NT levels and further increases olive oil-stimulated plasma NT levels. Inhibition of MAPK kinase (MEK)/ERK1/2 decreased fatty acid-stimulated NT release but increased AMP-activated protein kinase (AMPK) phosphorylation. In contrast, inhibition of AMPK further increased NT secretion and ERK1/2 phosphorylation mediated by FFAR1 or FFAR4. Our results indicate that FFAR4 plays a more critical role than FFAR1 in mediation of fat-regulated NT release and in inhibitory crosstalk between MEK/ERK1/2 and AMPK in the control of NT release downstream of FFAR1 and FFAR4.

UR - http://www.scopus.com/inward/record.url?scp=85050988580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050988580&partnerID=8YFLogxK

U2 - 10.1210/en.2018-00284

DO - 10.1210/en.2018-00284

M3 - Article

VL - 159

SP - 2939

EP - 2952

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 8

ER -